Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHA In Brief: NeoRx Biostent

This article was originally published in The Gray Sheet

Executive Summary

NeoRx Biostent: Initial clinical results with cytochalasin B drug/catheter combination product find that 20% of patients with the treatment (six of 30) experienced post-procedure clinical events such as myocardial infarction, death, or revascularization, compared to 38% (five of 13) patients receiving a placebo, researchers report at the AHA conference in Orlando. Results were reported by Robert Wilensky, MD, University of Pennsylvania. A Phase II, 350-patient study is expected to begin in the second quarter of 1998, the company says. NeoRx is developing Biostent in collaboration with Schwarz Pharma A.G...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel